drugset / Trial / NCT04353128

Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.

NCT04353128

RandomizedParallel-groupQuadruple-blindPrevention

Summary

There is an urgent need to evaluate interventions that can prevent the infection with SARS-CoV 2 of healthcare workers at risk. Melatonin is an inexpensive and safe product with protective effect in both bacterial and viral infections likely due to its anti-inflammatory and anti-oxidative effects. This randomized controlled trial seeks to evaluate is efficacy as a prophylaxis in healthcare workers exposed to the virus in their clinical practice.

Timeline

Start
2020-04-20
Primary completion
2020-10-01
Completion
2020-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 2 mg Oral

Indications